Altamira Therapeutics Ltd (CYTOF) USD0.002

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore/ SemaPhore platforms). The Company has over two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. Its delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. AM-401, the drug product is based on its OligoPhore technology.